Compare Heron Therapeutics Inc (HRTX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vale SA — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Vale SA trades at $14.24 (market cap $59.07B). The key difference: Vale SA is far larger — about 645.9× Heron Therapeutics Inc's market cap, and Vale SA pays a 8.93% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | VALE | |
|---|---|---|
Market Cap | $91.46M | $59.07B |
Sector | Health | Basic Materials |
52-Week High | $1.96 | $17.82 |
52-Week Low | $0.39 | $9.53 |
Enterprise Value | $189.36M | $75.99B |
Dividend Yield | — | 8.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
VALE trades at $14.08, down 0.78% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported $38.4B revenue for 2025 with net income of $2.35B, though earnings have missed expectations in two of the last three quarters. Recent news highlights governance challenges and a $2.6B decarbonization investment plan announced in June 2026.
While analyst consensus remains cautiously optimistic with a $17.63 price target, declining profit margins and recent earnings misses present headwinds. The stock offers value with reasonable P/E and EV/EBITDA multiples, but investors face risks from commodity price volatility and execution challenges in the company's strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
